Hematologic Malignancy Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following hematologic malignancy clinical trials:


Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia


Myelodysplastic Syndrome

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB) (Fibrogen)

Treatment agent: Roxadustat
PI: Jarrod Holmes, MD
Study Coordinator: Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03263091


Chronic Lymphocytic Leukemia

A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas

Treatment agent:CG-806
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03893682